PLK1-Targeted Fluorescent Tumor Imaging with High Signal-to-Background Ratio

被引:19
作者
Hou, Ji-Ting [1 ,4 ]
Ko, Kyung-Phil [2 ]
Shi, Hu [3 ]
Ren, Wen Xiu [1 ]
Verwilst, Peter [1 ]
Koo, Seyoung [1 ]
Lee, Jin Yong [3 ]
Chi, Sung-Gil [2 ]
Kim, Jong Seung [1 ]
机构
[1] Korea Univ, Dept Chem, Seoul 02841, South Korea
[2] Korea Univ, Dept Life Sci, Seoul 02841, South Korea
[3] Sungkyunkwan Univ, Dept Chem, Suwon 16419, South Korea
[4] Hube Engn Univ, Hube Collaborat Innovat Ctr Biomass Convers & Util, Xiaogan 432000, Peoples R China
基金
新加坡国家研究基金会;
关键词
PLK1; SBE13; targeted imaging; high SBR ratio; fluorescence; KINASE; 1; CANCER THERAPEUTICS; IN-VIVO; POLO; PLK1; AGENTS; DESIGN; PRINCIPLES; THERAPY; PEPTIDE;
D O I
10.1021/acssensors.7b00544
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
As significantly expressed during cell division, polo-like kinase 1 (PLKl) plays crucial roles in numerous mitotic events and has attracted interest as a potential therapeutic marker in oncological drug discovery. We prepared two small molecular fluorescent probes, 1 and 2, conjugated to SBE13 (a type II PLK1 inhibitor) to investigate the PLK1-targeted imaging of cancer cells and tumors. Enzymatic docking studies, molecular dynamics simulations, and in vitro and in vivo imaging experiments all supported the selective targeting and visualization of PLK1 expressing cells by probes 1 and 2, and probe 2 was successfully demonstrated to image PLK1-upregulated tumors with remarkable signal-to-background ratios. These findings represent the first example of small-molecule based fluorescent imaging of tumors using PLKl as a target, which could provide new avenues for tumor diagnosis and precision therapeutics.
引用
收藏
页码:1512 / 1516
页数:5
相关论文
共 31 条
[21]   Fluorescence-guided surgery with live molecular navigation - a new cutting edge [J].
Nguyen, Quyen T. ;
Tsien, Roger Y. .
NATURE REVIEWS CANCER, 2013, 13 (09) :653-662
[22]   Polo on the rise -: from mitotic entry to cytokinesis with Plk1 [J].
Petronczki, Mark ;
Lenart, Peter ;
Peters, Jan-Michael .
DEVELOPMENTAL CELL, 2008, 14 (05) :646-659
[23]   Principles in the design of ligand-targeted cancer therapeutics and imaging agents [J].
Srinivasarao, Madduri ;
Galliford, Chris V. ;
Low, Philip S. .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (03) :203-219
[25]   Polo-like kinases (Plks) and cancer [J].
Takai, N ;
Hamanaka, R ;
Yoshimatsu, J ;
Miyakawa, I .
ONCOGENE, 2005, 24 (02) :287-291
[26]   Selective Visualization of Cyclooxygenase-2 in Inflammation and Cancer by Targeted Fluorescent Imaging Agents [J].
Uddin, Md. Jashim ;
Crews, Brenda C. ;
Blobaum, Anna L. ;
Kingsley, Philip J. ;
Gorden, D. Lee ;
McIntyre, J. Oliver ;
Matrisian, Lynn M. ;
Subbaramaiah, Kotha ;
Dannenberg, Andrew J. ;
Piston, David W. ;
Marnett, Lawrence J. .
CANCER RESEARCH, 2010, 70 (09) :3618-3627
[27]   Rational principles for modulating fluorescence properties of fluorescein [J].
Ueno, T ;
Urano, Y ;
Setsukinai, K ;
Takakusa, H ;
Kojima, H ;
Kikuchi, K ;
Ohkubo, K ;
Fukuzumi, S ;
Nagano, T .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (43) :14079-14085
[28]   Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results [J].
van Dam, Gooitzen M. ;
Themelis, George ;
Crane, Lucia M. A. ;
Harlaar, Niels J. ;
Pleijhuis, Rick G. ;
Kelder, Wendy ;
Sarantopoulos, Athanasios ;
de Jong, Johannes S. ;
Arts, Henriette J. G. ;
van der Zee, Ate G. J. ;
Bart, Joost ;
Low, Philip S. ;
Ntziachristos, Vasilis .
NATURE MEDICINE, 2011, 17 (10) :1315-U202
[29]   Polo-like Kinase 1 (PLK1) Regulates Interferon (IFN) Induction by MAVS [J].
Vitour, Damien ;
Dabo, Stephanie ;
Pour, Malek Ahmadi ;
Vilasco, Myriam ;
Vidalain, Pierre-Olivier ;
Jacob, Yves ;
Mezel-Lemoine, Mariana ;
Paz, Suzanne ;
Arguello, Meztli ;
Lin, Rongtuan ;
Tangy, Frederic ;
Hiscott, John ;
Meurs, Eliane F. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (33) :21797-21809
[30]   Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer [J].
Wang, Xinning ;
Huang, Steve S. ;
Heston, Warren D. W. ;
Guo, Hong ;
Wang, Bing-Cheng ;
Basilion, James P. .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (11) :2595-2606